Brief: Gentian Diagnostics Q2 EBITDA Loss At NOK 1.2 Mln

Gentian Diagnostics ASA

25/08/2022 07:23

Aug 25 (Reuters) - Gentian Diagnostics ASA  GENT.OL :
    * SALES OF MNOK 30.1 IN 2Q22, UP 22% AND 19% ORGANICALLY
FROM 2Q21
DESPITE COVID-19 RELATED LOGISTICS CHALLENGES IN CHINA
    * FOR H2 2022 AIMS TO EXPAND FOOTPRINT VIA ADDITIONAL
REGULATORY
APPROVALS INCLUDING IVDR, AND FURTHER CLINICAL STUDIES
    * Q2 EBITDA ENDED AT MNOK -1.2 (MNOK -0.9) FOR 2Q22

Source text for Eikon:  ID:nObi6LKvYa 
Further company coverage:  GENT.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))